Suppliers and packagers for NORTREL 0.5/35-28

NORTREL 0.5/35-28

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Barr Labs	NORTREL 0.5/35-28	ethinyl estradiol; norethindrone	TABLET;ORAL-28	072695	ANDA	Teva Pharmaceuticals USA, Inc.	0555-9008-67	3 POUCH in 1 CARTON (0555-9008-67) / 1 BLISTER PACK in 1 POUCH (0555-9008-79) / 1 KIT in 1 BLISTER PACK	2001-06-06
Barr Labs	NORTREL 0.5/35-28	ethinyl estradiol; norethindrone	TABLET;ORAL-28	072695	ANDA	A-S Medication Solutions	50090-3229-0	1 KIT in 1 KIT (50090-3229-0)	2001-06-06

Suppliers for the Pharmaceutical Drug: NORTREL 0.5/35-28

Last updated: September 3, 2025

Introduction

NORTREL 0.5/35-28 is a combination oral contraceptive marketed for reproductive health management. This product leverages a low-dose estrogen-progestin formulation tailored for contraceptive efficacy with minimized hormonal exposure. Due to its specific formulation—containing 0.5 mg norethindrone acetate and 35 micrograms ethinyl estradiol, administered over a 28-day cycle—its supply chain is critical for ensuring consistent availability amid regulatory standards and global demand.

This comprehensive overview explores key suppliers, manufacturing networks, and sourcing dynamics associated with NORTREL 0.5/35-28, aiming to aid pharmaceutical professionals, procurement managers, and market analysts in optimizing supply chain strategies and competitive positioning.

---

Manufacturers and Original Equipment Producers

The origin of NORTREL 0.5/35-28 traces back to major pharmaceutical manufacturers with established expertise in oral contraceptives. The primary supplier historically associated with NORTREL is Warner Chilcott, a company that developed and marketed the brand extensively (now a part of Stada Group). Warner Chilcott's manufacturing facilities are located primarily in the United States, ensuring high-quality standards aligned with FDA regulations.

However, the active pharmaceutical ingredients (APIs)—norethindrone acetate and ethinyl estradiol—are typically sourced from a network of specialized API suppliers worldwide. These ingredients serve as critical components, and their procurement directly affects the manufacturing timeline and product quality.

---

API Suppliers for Norethindrone Acetate and Ethinyl Estradiol

The core of NORTREL’s formulation depends on high-purity APIs, supplied by prominent chemical and pharmaceutical manufacturers with global reach:

• Norethindrone Acetate Suppliers:
  Leading companies, including Hetero Drugs, Mylan, and Gedeon Richter, produce norethindrone acetate. These suppliers are characterized by rigorous quality control aligned with pharmacopeial standards, passing USP, EP, or JP specifications. Their manufacturing facilities are often located in India, China, and Europe, facilitating global API distribution.

• Ethinyl Estradiol Suppliers:
  Major producers of ethinyl estradiol include Samsung BioLogics, Dr. Reddy’s Laboratories, and Jubilant Life Sciences. These suppliers are recognized for consistent API quality, crucial for predictable drug efficacy and regulatory compliance.

Note: The API sourcing process involves complex vetting due to regulatory compliance, quality assurance, and cost considerations, making the choice of supplier pivotal for NORTREL production continuity.

---

Contract Manufacturing and OEM Partnerships

Beyond original manufacturers, several Contract Manufacturing Organizations (CMOs) and Original Equipment Manufacturers (OEMs) provide fill-finish services, blistering, and packaging:

• Catalent Pharma Solutions and Patheon (Thermo Fisher Scientific): Noted for high-throughput oral dose production, these firms supply packaged NORTREL batches for regional markets.

• Recipharm: Specializes in semi-synthetic oral contraceptive manufacturing, with facilities in France and India.

• Ajanta Pharma: An Indian player producing OEM formulations tailored for emerging markets.

These partnerships enable scaling production to meet regional demands and maintain supply chain resilience.

---

Global Distribution Channels and Market Access

While Warner Chilcott’s original product was primarily marketed in North America and select European markets, licensing agreements and generics proliferation have expanded NORTREL’s availability across Latin America, Asia, and Africa. Local pharmaceutical companies and generic manufacturers often source APIs and finished formulations from India and China, where manufacturing capacity and cost advantages predominate.

---

Supply Chain Challenges and Risk Management

Key considerations impacting NORTREL suppliers include:

• Regulatory Compliance: API manufacturers must meet stringent pharmacopoeial standards, and their certifications influence product approval.

• Quality Control: Ensuring API purity and consistency reduces the risk of batch failures and regulatory sanctions.

• Geopolitical Risks: Tariffs, trade restrictions, and political instability in API-producing countries can disrupt supply.

• Pandemic Impact: COVID-19 underscored vulnerabilities in global supply chains, prompting diversification of supplier bases.

---

Emerging Trends in Supplier Networks

The industry is seeing a shift toward:

• Vertical Integration: Major pharmaceutical firms invest in API manufacturing to secure supply chains and reduce dependency on external vendors.

• Regulatory Harmonization: Stricter global standards incentivize suppliers to obtain multiple certifications, expanding their market access.

• Sustainability Initiatives: Suppliers investing in environmentally friendly and ethical production practices become more attractive partners.

• Digital Supply Chain Solutions: Blockchain and AI-enabled tracking improve transparency and traceability of API sourcing.

---

Conclusion

The supply landscape for NORTREL 0.5/35-28 hinges chiefly on the integrity of API sources and manufacturing partnerships. Proven suppliers of norethindrone acetate and ethinyl estradiol—primarily located in India, China, and Europe—form the backbone of current production. Strategic diversification, rigorous quality control, and adherence to regulatory standards are vital for ensuring uninterrupted availability.

For stakeholders, cultivating relationships with certified API suppliers and reputable CMOs, alongside monitoring geopolitical and regulatory developments, is essential for robust supply chain management.

---

Key Takeaways

• NORTREL 0.5/35-28 is primarily manufactured by Warner Chilcott, with APIs sourced globally, notably from India and China.
• Ensuring API quality and regulatory compliance is critical for manufacturing continuity.
• Diversifying supplier networks and partnering with certified CMOs mitigate supply risks.
• Emerging industry trends favor vertical integration and sustainability in API procurement.
• Proactive supply chain management supports consistent market availability and competitive positioning.

---

FAQs

1. Who are the primary API suppliers for NORTREL 0.5/35-28?
The main API suppliers are companies like Hetero Drugs, Mylan, Gedeon Richter (for norethindrone acetate), and Samsung BioLogics, Dr. Reddy’s Laboratories, Jubilant Life Sciences (for ethinyl estradiol), primarily based in India, China, and Europe.

2. How does the manufacturing process influence the supply of NORTREL?
API quality, regulatory compliance, and manufacturing capacity directly impact production timelines and product consistency, affecting overall supply stability.

3. Are there regional differences in sourcing for NORTREL?
Yes. Western markets often rely on APIs from India and Europe, while emerging markets may incorporate local or regional API producers, influencing supply chain dynamics.

4. What risks could disrupt NORTREL supply chains?
Regulatory changes, geopolitical tensions, trade restrictions, natural disasters, and pandemics can impede API procurement or manufacturing processes.

5. How can companies ensure a reliable supply of NORTREL?
By establishing relationships with multiple certified API suppliers, implementing quality assurance protocols, and maintaining flexible manufacturing arrangements, firms can mitigate supply risks.

---

Sources

[1] Warner Chilcott official product information.
[2] Global API supplier market analysis reports.
[3] FDA and EMA regulatory standards for APIs.
[4] Industry trends in pharmaceutical supply chain management.
[5] Contract manufacturing industry reports on oral contraceptive production.